These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
859 related articles for article (PubMed ID: 1995310)
1. GM-CSF therapy for delayed engraftment after autologous bone marrow transplantation. Brandwein JM; Nayar R; Baker MA; Sutton DM; Scott JG; Sutcliffe SB; Keating A Exp Hematol; 1991 Mar; 19(3):191-5. PubMed ID: 1995310 [TBL] [Abstract][Full Text] [Related]
2. Interleukin-3 followed by GM-CSF for delayed engraftment after autologous bone marrow transplantation. Crump M; Couture F; Kovacs M; Saragosa R; McCrae J; Brandwein J; Huebsch L; Beauregard-Zollinger L; Keating A Exp Hematol; 1993 Mar; 21(3):405-410. PubMed ID: 8440338 [TBL] [Abstract][Full Text] [Related]
3. Proliferative response of human marrow myeloid progenitor cells to in vivo treatment with granulocyte colony-stimulating factor alone and in combination with interleukin-3 after autologous bone marrow transplantation. Lemoli RM; Fortuna A; Fogli M; Gherlinzoni F; Rosti G; Catani L; Gozzetti A; Miggiano MC; Tura S Exp Hematol; 1995 Dec; 23(14):1520-6. PubMed ID: 8542941 [TBL] [Abstract][Full Text] [Related]
4. Differential sensitivity of adherent CFU-blast, CFU-mix, BFU-E, and CFU-GM to mafosfamide: implications for adjusted dose purging in autologous bone marrow transplantation. Carlo-Stella C; Mangoni L; Almici C; Garau D; Craviotto L; Piovani G; Caramatti C; Rizzoli V Exp Hematol; 1992 Mar; 20(3):328-33. PubMed ID: 1568448 [TBL] [Abstract][Full Text] [Related]
5. Comparison of in vivo and in vitro effects of granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with acute myeloid leukemia. Estrov Z; Estey EH; Andreeff M; Talpaz M; Kurzrock R; Reading CL; Deisseroth AB; Gutterman JU Exp Hematol; 1992 Jun; 20(5):558-64. PubMed ID: 1587302 [TBL] [Abstract][Full Text] [Related]
6. Use of granulocyte-macrophage colony-stimulating factor (GM-CSF) in combination with hydroxyurea as post-transplant therapy in chronic myelogenous leukemia patients autografted with unmanipulated hematopoietic cells. Carlo-Stella C; Regazzi E; Andrizzi C; Savoldo B; Garau D; Montefusco E; Vignetti M; Mandelli F; Rizzoli V; Meloni G Haematologica; 1997; 82(3):291-6. PubMed ID: 9234574 [TBL] [Abstract][Full Text] [Related]
7. In vitro sensitivity of post-bone marrow transplantation CFU-GM and BFU-E to TNF-alpha and IFN-gamma. Papadakis V; Ferguson KF; Heller G; Kernan NA Exp Hematol; 1995 Dec; 23(14):1422-30. PubMed ID: 8542927 [TBL] [Abstract][Full Text] [Related]
8. The use of recombinant human granulocyte-macrophage colony stimulating factor for the treatment of delayed engraftment following high dose therapy and autologous hematopoietic stem cell transplantation for lymphoid malignancies. Vose JM; Bierman PJ; Kessinger A; Coccia PF; Anderson J; Oldham FB; Epstein C; Armitage JO Bone Marrow Transplant; 1991 Feb; 7(2):139-43. PubMed ID: 1675592 [TBL] [Abstract][Full Text] [Related]
9. Effects of in vivo treatment with PIXY321 (GM-CSF/IL-3 fusion protein) on proliferation kinetics of bone marrow and blood myeloid progenitor cells in patients with sarcoma. Broxmeyer HE; Benninger L; Cooper S; Hague N; Benjamin RS; Vadhan-Raj S Exp Hematol; 1995 Apr; 23(4):335-40. PubMed ID: 7895781 [TBL] [Abstract][Full Text] [Related]
10. Engraftment with peripheral blood stem cells using noncontrolled-rate cryopreservation: comparison with autologous bone marrow transplantation. Rosenfeld CS; Gremba C; Shadduck RK; Zeigler ZR; Nemunaitis J Exp Hematol; 1994 Mar; 22(3):290-4. PubMed ID: 7509292 [TBL] [Abstract][Full Text] [Related]
11. Modulation of the activity of a human granulocyte-macrophage colony-stimulating factor/interleukin-3 fusion protein (pIXY 321) by the macrocyclic lactone protein kinase C activator bryostatin 1. McCrady CW; Li F; Pettit GR; Grant S Exp Hematol; 1993 Jul; 21(7):893-900. PubMed ID: 7686503 [TBL] [Abstract][Full Text] [Related]
12. Successful autologous transplantation of blood stem cells mobilized with recombinant human granulocyte-macrophage colony-stimulating factor. Haas R; Ho AD; Bredthauer U; Cayeux S; Egerer G; Knauf W; Hunstein W Exp Hematol; 1990 Feb; 18(2):94-8. PubMed ID: 1968009 [TBL] [Abstract][Full Text] [Related]
13. G-CSF primed peripheral blood progenitor cells in autologous bone marrow transplantation: parameters affecting bone marrow engraftment. Bolwell BJ; Fishleder A; Andresen SW; Lichtin AE; Koo A; Yanssens T; Burwell R; Baucco P; Green R Bone Marrow Transplant; 1993 Dec; 12(6):609-14. PubMed ID: 7511016 [TBL] [Abstract][Full Text] [Related]
14. Effect of stem cell factor (c-kit ligand), granulocyte-macrophage colony stimulating factor and interleukin 3 on hematopoietic progenitors in human long-term bone marrow cultures. Lemoli RM; Gulati SC Stem Cells; 1993 Sep; 11(5):435-44. PubMed ID: 7694721 [TBL] [Abstract][Full Text] [Related]
15. Successful autografting following myeloablative conditioning therapy with blood stem cells mobilized by chemotherapy plus rhG-CSF. Hohaus S; Goldschmidt H; Ehrhardt R; Haas R Exp Hematol; 1993 Apr; 21(4):508-14. PubMed ID: 7681782 [TBL] [Abstract][Full Text] [Related]
16. Effects of recombinant granulocyte colony-stimulating factor (rG-CSF) and recombinant granulocyte-macrophage colony-stimulating factor (rGM-CSF) on acute radiation hematopoietic injury in mice. Tanikawa S; Nakao I; Tsuneoka K; Nara N Exp Hematol; 1989 Sep; 17(8):883-8. PubMed ID: 2475360 [TBL] [Abstract][Full Text] [Related]
17. Cytokine-primed bone marrow stem cells vs. peripheral blood stem cells for autologous transplantation: a randomized comparison of GM-CSF vs. G-CSF. Weisdorf D; Miller J; Verfaillie C; Burns L; Wagner J; Blazar B; Davies S; Miller W; Hannan P; Steinbuch M; Ramsay N; McGlave P Biol Blood Marrow Transplant; 1997 Oct; 3(4):217-23. PubMed ID: 9360784 [TBL] [Abstract][Full Text] [Related]
18. Use of continuous infusion granulocyte-macrophage colony-stimulating factor alone or followed by granulocyte colony-stimulating factor to enhance engraftment following high-dose chemotherapy and autologous bone marrow transplantation for lymphoid malignancies. Vose JM; Bierman PJ; Ruby E; Reed EC; Bishop MR; Tarantolo S; Kessinger A; Armitage JO Bone Marrow Transplant; 1996 Jun; 17(6):951-6. PubMed ID: 8807099 [TBL] [Abstract][Full Text] [Related]
19. Recombinant GM-CSF in patients with poor graft function after bone marrow transplantation. Klingemann HG; Eaves AC; Barnett MJ; Reece DE; Shepherd JD; Belch AR; Brandwein JM; Langleben A; Koch PA; Phillips GL Clin Invest Med; 1990 Apr; 13(2):77-81. PubMed ID: 2191816 [TBL] [Abstract][Full Text] [Related]
20. Recovery of CFU-GM from cryopreserved marrow and in vivo evaluation after autologous bone marrow transplantation are predictive of engraftment. Douay L; Gorin NC; Mary JY; Lemarie E; Lopez M; Najman A; Stachowiak J; Giarratana MC; Baillou C; Salmon C Exp Hematol; 1986 Jun; 14(5):358-65. PubMed ID: 3519263 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]